enGene Appoints Lota S. Zoth, CPA, as Member of the Board of Directors
BOSTON and MONTREAL, Dec. 19, 2023 /PRNewswire/ – enGene Holdings Inc. (“enGene,”Nasdaq: ENGN), a clinical-stage genetic medicines company whose lead program is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the appointment of Lota S. Zoth, CPA, as a member of the Board of Directors and Audit Committee Chair.
Related news for (ENGN)
- enGene (NASDAQ:ENGN) Reports Oversubscribed $200 M Private Placement
- enGene Appoints Lee Giguere as Chief Legal Officer and Corporate Secretary
- enGene Reports Full Year 2023 Financial Results and Recent Operational Progress
- enGene Appoints Ryan Daws as Chief Financial Officer
- enGene Announces Expanded $50 Million Debt Facility with Hercules Capital